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CYCLODEXTRIN more , freeze drying and spray drying are expensive and 
time - consuming processes . There is therefore a need to 
This application is a Divisional Patent Application of U . S . provide an improved process for the production of pharma 
patent application Ser . No . 14 / 333 , 417 , filed Jul . 16 , 2014 , ceuticals comprising substituted cyclodextrin - based excipi 
which claims priority to and the benefit of U . S . Provisional 5 ents . 
Patent Application No . 61 / 847 , 509 , filed Jul . 17 , 2013 . The As described in the Examples , the inventors carefully 
contents of each of these patent applications is incorporated studied the batch SBE - B - CD production method that is 
herein for all purposes in their entirety . described in U . S . Pat . No . 5 , 376 , 645 ( Stella et al , 1994 ) , and 
The invention relates to cyclodextrins and derivatised experimented with the stoichiometry of the reaction , and 
cyclodextrins , such as sulphoalkyl ether ß - cyclodextrin , and 10 have devised a significantly improved continuous flow syn 
in particular to a novel method for the synthesis thereof . The thetic method for producing sulphoalkyl ether cyclodextrins , 
invention is particularly concerned with producing sul - such as SBE - B - CD . 
phobutyl ether B - cyclodextrin . The invention extends to Hence , according to a first aspect of the invention , there 
novel compositions comprising sulphoalkyl ether ß - cyclo - is provided a method for preparing sulphoalkyl ether ß - cy 
dextrins , and to the uses of such compositions , for example 15 clodextrin , the method comprising contacting cyclodextrin 
as excipients in order to improve the solubility and chemical with a base to form activated cyclodextrin , and separately 
stability of drugs in solution . contacting the activated cyclodextrin with an alkyl sultone to 
Sulphobutyl ether ß - cyclodextrin ( SBE - B - CD or SBECD ) form sulphoalkyl ether ß - cyclodextrin , characterised in that 
is one of a class of polyanionic , hydrophilic water soluble the sulphoalkylation reaction is carried out under continuous 
cyclodextrin derivatives . The parent B - cyclodextrin can 20 flow conditions . 
form an inclusion complex with certain active pharmaceu - In a second aspect , there is provided sulphoalkyl ether 
tical ingredients ( API ) with two benefits , the apparent aque B - cyclodextrin obtained or obtainable by the method accord 
ous solubility of the API increases and , if labile functional ing to the first aspect . 
groups are included , chemical stability is improved . How The inventors have found that the continuous flow nature 
ever , the parent B - cyclodextrin suffers from two problems , 25 of the sulphoalkylation reaction in the method of the first 
including lower aqueous solubility and nephrotoxicity when aspect results in a surprisingly superior process compared to 
given via injection , e . g . the intravenous route . Derivatisation the prior art batch process , because it exhibits a greater 
of ß - cyclodextrin ( and its variants a and y - cyclodextrin ) has reaction efficiency and results in a much tighter control of 
been shown to be beneficial with respect to both of these two substitution of the resultant sulphoalkyl ether ß - cyclodex 
defects . The first derivatised cyclodextrin was the hydroxy - 30 trin , which is preferably sulphobutyl ether B - cyclodextrin 
propyl derivative , which was later followed by sulphobutyl ( i . e . SBE - B - CD ) . Indeed , the continuous flow synthesis 
ether . These two derivatised cyclodextrins are the most process of the invention substantially less than 50 % of the 
commercially significant . amount of base ( which is preferably sodium hydroxide ) that 
FIG . 1 illustrates the chemical reaction for the synthesis is used in the prior art batch process , and only a 7 : 1 molar 
of SBE - B - CD from the reagents B - cyclodextrin ( B - CD ) and 35 ratio of the alkyl sultone ( which is preferably , 1 , 4 - butane 
1 , 4 - butane sultone ( BS ) . U . S . Pat . No . 6 , 153 , 746 ( Shah et al , sultone ) to cyclodextrin instead of the 10 : 1 used by the prior 
2000 ) describes a batch synthesis of SBE - B - CD , the process art method . This finding was completely unexpected , since 
being effectively divided into three main stages , i . e . initial the inventors ' expectation was that , at best , an equivalent 
reagent dissolution , a sulphoalkylation reaction and final synthetic efficiency between the batch and continuous flow 
reaction quenching . The reaction is then followed by down - 40 methods would be seen . Accordingly , by using the continu 
stream processing and purification , and ultimate isolation of ous flow method of the first aspect , the alkyl sultone can 
the solid SBE - B - CD material . However , a problem associ - react with the cyclodextrin more efficiently and completely 
ated with using a batch synthetic method is that a high to thereby generate higher degrees of substitution with more 
proportion of lower substituted SBE - B - CD is observed . efficient use of the starting materials . It has also been noted 
There is therefore a need to provide an improved synthetic 45 that lower volumes of water are necessary to achieve chemi 
method for producing substituted cyclodextrins , such as cal coupling . 
SBE - B - CD . In one embodiment of the method of the invention , the 
SBE - B - CD is currently used as an effective pharmaceu - sulphoalkylation reaction is carried out under continuous 
tical excipient , and has been given the trade name Capti - flow conditions , whereas the activation reaction may be 
sol® . To date , there are five US FDA - approved , SBE - B - CD - 50 carried out either continuously , batch , or fed - batch . Prefer 
enabled drug products on the market : Nexterone ( Baxter a bly , however , the activation reaction is carried out as a 
International ) ; Geodon ( Pfizer ) ; Cerenia ( Zoetis ) ; Kyprolis batch process while the sulphoalkylation reaction is carried 
( Onyx ) ; Abilify ( Bristol Myers Squibb ) . out under continuous flow conditions . 
In addition , as described in U . S . Pat . No . 6 , 632 , 803B1 Problems associated with prior art methods which are ( Harding , 2003 ) , Pfizer has developed the clinically impor - 55 fully batch , or fully continuous , ( i . e . with respect to both the 
tant antifungal drug , voriconazole , formulated with SBE - B activation stage and the sulphoalkylation reaction stage ) are 
CD , as excipient . If Shah ' s and Harding ' s patents are that they result in the production of high concentrations of 
considered together , the overall process to produce an inject - by - products ( e . g . dimerisation products ) , produce SBE - B 
able form of voriconazole follows a 10 - step scheme , as CD with low average degrees of substitution , as well leave 
shown in FIG . 22 . Production of the SBE - B - CD excipient is 60 unreacted alkyl sultone . Accordingly , the method of the 
represented by the six white boxes , and production of the invention , in which the activation stage is batch and the 
final injectable voriconazole ( i . e . formulation of the API sulphoalkylation reaction stage is continuous , results in 
with the excipient ) is represented by the four grey boxes . lower concentrations of by - products , SBE - B - CD with a 
The problems with this process are that it includes many higher average degree of substitution , and also most if not all 
steps , one of which is the transportation of the SBE - B - CD 65 of the alkyl sultone is reacted . 
from the fine chemical manufacturing plant to the customer Preferably , the cyclodextrin is a - , B - or y - cyclodextrin . It 
who adds the active ingredient , e . g . voriconazole . Further will be appreciated that a - and y - cyclodextrin can be used as 
US 10 , 239 , 961 B2 
pharmaceutical excipients for instance in commercially During their research , the inventors carefully considered 
available drugs such as Prostavasin , Opalamon ( B - CD ) and the prior art batch process , and found that the base , 
Voltaren ( modified y - CD ) . Most preferably , however , the employed to chemically activate the B - cyclodextrin 
cyclodextrin is ß - cyclodextrin . hydroxyl groups , has a tendency to attack the alkyl sultone 
The alkyl sultone may comprise propane sultone . Thus , 5 reagent , thereby reducing its effective concentration , and , as 
sulphoalkyl ether B - cyclodextrin preferably comprises sul - a result , reduces the average degree of substitution in the 
phopropyl ether ß - cyclodextrin ( SPE - B - CD ) . final product with the generation of low degree of substitu 
However , most preferably the alkyl sultone comprises tion species . Accordingly , during the method of the first 
1 , 4 - butane sultone . Preferably , therefore , the sulphoalkyl aspect , it is preferred that the base is kept separate from the 
ether B - cyclodextrin comprises sulphobutyl ether B - cyclo - 10 alkyl sultone , preferably 1 , 4 - butane sultone . Preferably , the 
dextrin ( SBE - B - CD ) . The resultant substituted sulphoalkyl base is first separately reacted with the cyclodextrin in order 
ether B - cyclodextrin according to the second aspect is novel to produce the activated cyclodextrin . This reaction is pref 
per se because it exhibits a higher average degree of sub - erably conducted in a first reservoir vessel . The activation 
stitution , for a lower input of alkyl sultone and base than that reaction may therefore be carried out as a batch or fed - batch 
which is produced using the known batch process . The batch 15 process . Preferably , the base and cyclodextrin form an 
method of preparing substituted sulphoalkyl ether B - cyclo - aqueous solution . The activation reaction is preferably con 
dextrin produces a higher concentration of lower degrees of ducted at a temperature of about 50 to 95° C . , more 
sulphoalkyl ether ß - cyclodextrin substitution than that pro - preferably 60 to 70° C . The activation reaction is preferably 
duced using continuous flow . As shown in FIGS . 20 and 25 , conducted at atmospheric pressure . 
the continuous flow process of the invention however results 20 Preferably , the alkyl sultone is contained within a second 
in a lower concentration of lower substituted sulphoalkyl reservoir vessel . Preferably , the first and second vessels are 
ether B - cyclodextrin ( i . e . a degree of substitution value of not directly connected to each other , such that the sultone 
1 - 4 ) and surprisingly much higher concentrations of the and the base do not react with each other . 
higher substituted sulphoalkyl ether B - cyclodextrin ( i . e . The activated cyclodextrin ( i . e . aqueous solution ) and the 
individual degrees of substitution values of 4 - 13 ) . 25 alkyl sultone ( i . e . pure ) are preferably fed to a confluent 
Thus , preferably the average degree of substitution ( ADS ) 3 - way junction where they are allowed to react to produce 
of the sulphoalkyl ether B - cyclodextrin produced by the the substituted sulphoalkyl ether B - cyclodextrin . The acti 
method of the first aspect or the SBE - B - CD of the second vated aqueous cyclodextrin and the alkyl sultone are pref 
aspect is greater than 7 , more preferably 7 . 3 or more , more erably pumped at a controlled rate to the junction . 
preferably 8 or more , even more preferably 9 or more , and 30 The molar ratio of sultone ( preferably 1 , 4 - butane sultone ) 
most preferably 10 or more . The skilled person will appre - to cyclodextrin ( preferably ß - cyclodextrin ) is preferably 
ciate that it is possible to calculate the substitution degree between about 7 : 1 and 33 : 1 . Preferably , the molar ratio of 
( i . e . the substitution envelope ) by using the following For - sultone to cyclodextrin is 7 : 1 to 17 : 1 . 
mula : The sulphoalkylation reaction is preferably conducted at 
35 a temperature of 60 to 100° C . , more preferably 65 to 95° C . , 
ADS = E ( ( PAC ) x ( MT ) / SCAX100 / 100 and even more preferably 60 to 70° C . The sulphoalkylation 
where PAC refers to the peak area count ; MT refers to the reaction is preferably conducted at atmospheric pressure . 
migration time ; and SCA refers to the summation of cor - The alkylation reaction may be carried out in a continuous 
rected area . The inventors believe that this increased ADS is stirred tank reactor ( CSTR ) or a flow reactor with efficient 
an important feature of the invention . 40 mixing and of suitable length to allow the reaction to 
Thus , in a third aspect there is provided a composition complete within the reactor tubing . The activation of ß - cy 
comprising sulphobutyl ether B - cyclodextrin ( SBE - B - CD ) , clodextrin is an important process parameter prior to reac 
wherein the average degree of substitution ( ADS ) is 7 or tion and this must continue irrespective of the reactor 
more , preferably 7 . 3 or more , preferably 8 or more , even architecture . 
more preferably 9 or more , and most preferably 10 or more . 45 In a preferred embodiment , the method of the invention 
Since the batch method produces a higher proportion of comprises contacting the cyclodextrin in a batch or fed 
lower substituted SBE - B - CD than higher substituted SBE - batch reaction with the base to form activated cyclodextrin , 
B - CD , the continuous flow method of the invention provides and separately contacting the activated cyclodextrin with an 
a significant advantage . alkyl sultone to form sulphoalkyl ether B - cyclodextrin , 
Preferably , the composition of the third aspect comprises 50 wherein the sulphoalkylation reaction is carried out under 
SBE - B - CD having a Substitution Molecular Mass Fraction continuous flow conditions . ( SMF ) greater than 0 . 57 , more preferably greater than 0 . 58 , In a most preferred embodiment , therefore , the method 
and even more preferably greater than 0 . 59 . Preferably , the comprises separately reacting B - cyclodextrin with sodium 
composition of the third aspect comprises SBE - B - CD having hydroxide in a batch or fed - batch reaction to form activated 
an SMF greater than 0 . 60 , and more preferably greater than 55 B - cyclodextrin , and then separately contacting the activated 
0 . 61 . Example 8 describes how the SMF value can be B - cyclodextrin with 1 , 4 - butane sultone to form SBE - B - CD 
calculated with reference to FIG . 28 . under continuous flow conditions . 
The base may be an alkali metal hydroxide , for example The inventors have surprisingly demonstrated that it is 
sodium hydroxide , lithium hydroxide or potassium hydrox - possible to accurately control and manipulate the average 
ide . It is preferred that the base comprises sodium hydrox - 60 degree of substitution ( ADS ) of sulphoalkyl ether B - cyclo 
ide . dextrin produced in sulphoalkylation reaction by varying the 
The molar ratio of base ( which is preferably sodium sodium hydroxide concentration in the initial activation 
hydroxide ) to cyclodextrin is preferably within the range of reaction . 
2 : 1 to 22 : 1 , preferably 6 : 1 to 20 : 1 , more preferably 6 : 1 to Preferably , therefore , the method comprises controlling 
15 : 1 , and even more preferably 6 : 1 to 14 : 1 . The preferred 65 the average degree of substitution ( ADS ) of sulphoalkyl 
molar ratio of base to cyclodextrin is 6 : 1 to 14 : 1 . The most ether B - cyclodextrin in the sulphoalkylation reaction by 
preferred molar ratio of base to cyclodextrin is 6 : 1 to 15 : 1 . varying the base concentration in the initial activation reac 
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1 . 
tion . This is an important feature of the invention . Accord enough basis . Thirdly , one of the two expensive and time 
ingly , in another aspect , there is provided use of sodium consuming freeze or spray drying process steps can be 
hydroxide concentration for controlling the average degree avoided . 
of substitution ( ADS ) of sulphoalkyl ether B - cyclodextrin Preferably , the method comprises contacting the excipient 
produced in a sulphoalkylation reaction between activated 5 with an active pharmaceutical ingredient ( API ) to produce a 
cyclodextrin and an alkyl sultone . pharmaceutical composition without drying or isolating the 
Preferably , the use comprises carrying out an initial excipient  
activation reaction between cyclodextrin and the base to Preferably , the pharmaceutical excipient comprises sul 
form activated cyclodextrin . phobutyl ether B - cyclodextrin . 
To date , no one has appreciated that the concentration of Preferably , the active pharmaceutical ingredient com 
sodium hydroxide can be varied in the initial activation prises voriconazole , ziprasidone , aripiprazole , maropitant , 
reaction in order to control and manipulate the average amiodarone , or carfilzomib , or their salts , solvates , poly 
degree of substitution ( ADS ) of resultant sulphoalkyl ether morphs , pseudopolymorphs or co - crystals . 
B - cyclodextrin . In another embodiment , the method of the invention 
The unsubstituted parent B - CD is shown to induce irre - comprises separately reacting B - cyclodextrin with sodium 
versible nephrotic damage to the kidney cells when used as hydroxide to form activated B - cyclodextrin , and then sepa 
an excipient in injection formulations . SBE - B - CD causes rately contacting the activated B - cyclodextrin with 1 , 4 
reversible vacuolation of renal cells but not nephrotic dam - butane sultone to form SBE - B - CD , all under continuous flow 
age and is therefore preferred for use in injectable formu - 20 conditions . Advantageously , the stoichiometry of the reac 
lations . Given that the inventors have clearly demonstrated tion can be readily controlled by varying the flow rates of the 
that the method of the invention results in a lower concen - activated cyclodextrin solution and / or liquid sultone . 
tration of low degree of substitution SBE - B - CD species it is Hence , in another aspect of the invention , there is pro 
believed that the SBE - B - CD may cause lower levels of vided a method for preparing sulphoalkyl ether B - cyclodex 
physiological changes to renal cells . Accordingly , they 25 trin , the method comprising contacting cyclodextrin with a 
believe that the SBE - B - CD of the second aspect or the base to form activated cyclodextrin , and separately contact 
composition of the third aspect can be used to reduce ing the activated cyclodextrin with an alkyl sultone to form 
changes in renal cells when used as a drug delivery system . sulphoalkyl ether ß - cyclodextrin , characterised in that the 
Hence , in a fourth aspect there is provided the use of process is carried out under continuous flow conditions . 
sulphoalkyl ether ß - cyclodextrin of the second aspect , or the 30 All of the features described herein ( including accompa 
composition of the third aspect , as a drug delivery system . nying claims , abstract and drawings ) , and / or all of the steps 
of any method or process so disclosed , may be combined Preferably , the drug delivery system is an excipient , with any of the above aspects in any combination , except 
which preferably exhibits little or no side effects with regard combinations where at least some of such features and / or to renal physiology . Preferably , the sulphoalkyl ether ß - cy - , 35 steps are mutually exclusive . clodextrin comprises sulphobutyl ether B - cyclodextrin For a better understanding of the invention , and to show ( SBE - B - CD ) . how embodiments of the same may be carried into effect , In a fifth aspect , therefore , there is provided a pharma reference will now be made , by way of example , to the 
ceutical excipient comprising the sulphoalkyl ether ß - cyclo accompanying drawings , in which : 
dextrin of the second aspect , or the composition of the third 40 FIG . 1 shows the chemical reaction for the synthesis of 
aspect . sulphobutyl ether B - cyclodextrin ( SBE - B - CD ) from B - cy 
Preferably , therefore , the sulphoalkyl ether - ß - cyclodex - clodextrin ( CD ) and 1 , 4 - butane sultone ( BS ) ; 
trin comprises sulphobutyl ether B - cyclodextrin ( SBE - B - FIG . 2 is a schematic representation for an embodiment of 
CD ) . an apparatus for carrying out continuous flow ( CF ) synthesis 
Advantageously , as described in examples , use of the 45 for SBE - B - CD according to the invention ; 
continuous flow method of invention means that it is now FIG . 3 shows the actual lab - based apparatus for carrying 
possible to combine the two processes shown in FIG . 22 ( i . e . out a continuous flow synthesis for SBE - B - CD ; 
excipient production , and pharmaceutical production ) , to FIG . 4 is a graph showing the changing amount of NaOH 
result in the 6 - step process chain shown in FIG . 23 . at 7 : 1 and 10 : 1 BS / CD mole ratio ; 100 % nominal sodium 
Hence , in a sixth aspect , there is provided a method of 50 hydroxide is equivalent to the base content used in U . S . Pat . 
preparing a pharmaceutical composition , the method com - No . 5 , 376 , 645 ( Stella et a / 4994 ) 
prising preparing the pharmaceutical excipient according to FIG . 5 shows electropherograms of batch manufactured 
the fifth aspect , and contacting the excipient with an active SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 
pharmaceutical ingredient ( API ) to produce a pharmaceuti solid line and SBE - B - CD manufactured by a continuous 
cal composition . 55 flow process according to the invention , with a 8 : 1 butane 
In contrast to the process shown in FIG . 22 , the produc - sultone to ß - cyclodextrin molar ratio as the dotted line . The 
tion of the sulphobutyl ether cyclodextrin , acting as excipi - sodium hydroxide to B - CD molar ratio is 11 : 1 . 
ent , is now represented in FIG . 23 by just three white boxes FIG . 6 shows electropherograms of batch manufactured 
( instead of six ) , and formulation of the API with the excipi - SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 
ent to create the pharmaceutical product is represented by 60 solid line and SBE - B - CD manufactured by a continuous 
only three grey boxes ( instead of four ) . Accordingly , the flow process according to the invention , with a 11 : 1 butane 
method of the invention means that three of the steps shown sultone to B - cyclodextrin molar ratio as the dotted line . The 
in FIG . 22 can be omitted . Therefore , it is now unnecessary sodium hydroxide to B - CD molar ratio is 11 : 1 . 
to transport the sulphobutyl ether cyclodextrin from the fine FIG . 7 shows electropherograms of batch manufactured 
chemical manufacturer to the customer . This would also 65 SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 
include warehousing , etc . Secondly , the sulphoalkyl ether solid line and SBE - B - CD manufactured by a continuous 
B - cyclodextrin can be manufactured on a just - in - time , just flow process according to the invention , with a 14 : 1 butane 
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sultone to B - cyclodextrin molar ratio as the dotted line . The sultone to B - cyclodextrin molar ratio as the dotted line . The 
sodium hydroxide to B - CD molar ratio is 11 : 1 . sodium hydroxide to B - CD molar ratio is 9 : 1 . 
FIG . 8 shows electropherograms of batch manufactured FIG . 19 shows electropherograms of batch manufactured 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 
solid line and SBE - B - CD manufactured by a continuous 5 solid line and SBE - B - CD manufactured by a continuous 
flow process according to the invention , with a 17 : 1 butane flow process according to the invention , with a 10 : 1 butane 
sultone to B - cyclodextrin molar ratio as the dotted line . The sultone to ß - cyclodextrin molar ratio as the dotted line . The 
sodium hydroxide to B - CD molar ratio is 11 : 1 . sodium hydroxide to B - CD molar ratio is 11 : 1 . 
FIG . 9 shows electropherograms of batch manufactured FIG . 20 shows electropherograms of batch manufactured 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 10 SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah , et al 2000 ) as the 
solid line and SBE - B - CD manufactured by a continuous solid line and SBE - B - CD manufactured by a continuous 
flow process according to the invention , with a 19 : 1 butane flow process according to the invention , with a 10 : 1 butane 
sultone to B - cyclodextrin molar ratio as the dotted line . The sultone to B - cyclodextrin molar ratio as the dotted line . The 
sodium hydroxide to B - CD molar ratio is 11 : 1 . 16 sodium hydroxide to B - CD molar ratio is 14 : 1 . 
FIG . 10 shows electropherograms of batch manufactured FIG . 21 shows a Vapourtec integrated flow reactor and 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the associated equipment that will ultimately be preferred for 
solid line and SBE - B - CD manufactured by a continuous the integrated manufacture of the SBE - B - CD and API in a 
flow process according to the invention , with a 23 : 1 butane secondary pharmaceutical production manufacturing area to 
sultone to B - cyclodextrin molar ratio as the dotted line . The 20 produce the drug product . 
sodium hydroxide to B - CD molar ratio is 11 : 1 . FIG . 22 is a schematic representation of a conventional 
FIG . 11 shows electropherograms of batch manufactured process chain for voriconazole Injection Based on the stan 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the dard SBECD batch process and Fine Chemical Model 
solid line and SBE - B - CD manufactured by a continuous ( excipient production in white ; secondary pharmaceutical 
flow process according to the invention , with a 28 : 1 butane 25 production in grey ) . 
sultone to B - cyclodextrin molar ratio as the dotted line . The FIG . 23 is a schematic representation of a revised process 
sodium hydroxide to B - CD molar ratio is 11 : 1 . chain for voriconazole Injection Based on an SBECD con FIG . 12 shows electropherograms of batch manufactured tinuous flow ( CF ) process and Integrated Manufacture SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the Model ( excipient production in white ; secondary pharma 
solid line and SBE - B - CD manufactured by a continuous 30 30 ceutical production in grey ) . flow process according to the invention , with a 33 : 1 butane FIG . 24 is a chromatogram of sulphobutylether ß - cyclo 
sultone to ß - cyclodextrin molar ratio as the dotted line . The dextrin produced by the method described in U . S . Pat . No . sodium hydroxide to B - CD molar ratio is 11 : 1 . 6 , 153 , 746 ( Shah , 2000 ) , and tested according to the methods FIG . 13 shows electropherograms of batch manufactured 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 35 des the 3s described in United States Pharmacopoeia 35 / National For 
solid line and SBE - B - CD manufactured by a continuous mulary 30 ( USP35 / NF30 ) . HPLC conditions are based on a flow process according to the invention , with a 7 : 1 butane gradient separation with a CD - Screen - DAP column and 
sultone to B - cyclodextrin molar ratio as the dotted line . The ELSD detection . 
sodium hydroxide to B - CD molar ratio is 6 : 1 . FIG . 25 is a chromatogram of sulphobutylether ß - cyclo 
FIG . 14 shows electropherograms of batch manufactured 40 dextrin produced by the method according to the invention . 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the Reaction conditions correspond to those used to generate 
solid line and SBE - B - CD manufactured by a continuous FIG . 20 , and HPLC conditions are based on a gradient 
flow process according to the invention , with a 7 : 1 butane separation with a CD - Screen - DAP column and ELSD detec 
sultone to B - cyclodextrin molar ratio as the dotted line . The tion . 
sodium hydroxide to B - CD molar ratio is 9 : 1 . 45 FIG . 26 is a table showing shows a summary of the data 
FIG . 15 shows electropherograms of batch manufactured adding the Average Degree of Substitution data and disper 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the s ion data . 
solid line and SBE - B - CD manufactured by a continuous FIG . 27 is a table describing an attempt to produce 
flow process according to the invention , with a 7 : 1 butane material compliant with the USP35 / NF30 monograph with 
sultone to B - cyclodextrin molar ratio as the dotted line . The 50 the use of more moderate reaction conditions . 
sodium hydroxide to B - CD molar ratio is 11 : 1 . FIG . 28 is a graph showing substitution molecular mass 
FIG . 16 shows electropherograms of batch manufactured ratio for SBE - B - CD . 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the FIG . 29 is a graph showing the molecular weight and 
solid line and SBE - B - CD manufactured by a continuous individual degree of substitution for SBE - B - CD . 
flow process according to the invention , with a 7 : 1 butane 55 
sultone to B - cyclodextrin molar ratio as the dotted line . The EXAMPLE 
sodium hydroxide to B - CD molar ratio is 14 : 1 . 
FIG . 17 shows electropherograms of batch manufactured The inventors have developed a novel continuous flow 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the ( CF ) method for the synthesis of sulphoalkyl ether - ß - cyclo 
solid line and SBE - B - CD manufactured by a continuous 60 dextrin , for example sulphobutyl ether B - cyclodextrin ( SBE 
flow process according to the invention , with a 10 : 1 butane B - CD ) . The invention includes novel compositions compris 
sultone to B - cyclodextrin molar ratio as the dotted line . The ing sulphoalkyl ether B - cyclodextrins , and to therapeutic 
sodium hydroxide to B - CD molar ratio is 6 : 1 . uses of such compositions , for example to improve the 
FIG . 18 shows electropherograms of batch manufactured solubility and chemical stability of drugs in solution . 
SBE - B - CD ( U . S . Pat . No . 6 , 153 , 746 - Shah et al , 2000 ) as the 65 Materials 
solid line and SBE - B - CD manufactured by a continuous Beta cyclodextrin ( ß - CD ) , 1 , 4 - Butane Sultone ( BS ) , 
flow process according to the invention , with a 10 : 1 butane Water for injections and sodium hydroxide ( NaOH ) . 
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Laboratory Equipment CSTR ( 14 ) . As two phases are seen in the first chamber of 
Continuous stirred tank reactor ( CSTR ) vessel , Masterflex the CSTR ( 14 ) , it is most likely that small volumes of the 
pump , Hotplate stirrer , Water bath , PTFE tubing ( 2 mm ID / 4 heated reagents are delivered and react there . Provided that 
mm ID ) , Omnifit Connectors , Dialysis tubing ( Biotech the flow rate is not excessively high , the second chamber of 
grade , Cellulose Ester , 0 . 5 - 1 kDa MWCO ) . 5 the CSTR ( 14 ) and the receiving vessel both contain clear 
Methods liquid suggesting that the reaction is complete upon exit 
The set - up for the continuous flow experiments consisted from the first chamber of the CSTR ( 14 ) . High flow rates 
of two Masterflex pumps ( 8 , 10 ) connected to a double 10 will deliver unreacted material to the second chamber and , 
ml ( i . e . two 10 ml chambers ) jacketed continuous stirred in extreme circumstances , to the receiving vessel . The crude 
tank reactor ( CSTR ) or holding chamber ( 14 ) used as a 10 product was harvested in a 20 ml sample bottle . 
holding chamber / sight glass . The two pumps ( 8 , 10 ) were Continuous flow experiments were carried out at different 
connected to the CSTR / holding chamber ( 14 ) via a three drive speed combinations for pump ( 8 ) and ( 10 ) thus obtain 
way connector ( 12 ) and PTFE tubing . Non - return valves ing a series of BS : CD mole ratio , as shown in Tables 1 and 
were fitted in line in the vicinity of the three - way connector 
TABLE 1 
The relationship between pump drive speed and flow rate giving rise to different 
butane sultone - B - cyclodextrin molar ratios - constant B - cyclodextrin flow rate . 
Butane sultone B - CD 
Drive 
speed ( rpm ) 
Flow 
rate ( ml /min ) 
3 4 5 6 8 10 12 8 . 
0 . 27 0 . 36 0 . 45 0 . 54 0 . 63 0 . 72 0 . 90 1 . 08 0 . 72 
2 . 65e - 3 3 . 53e - 3 4 . 41e - 3 5 . 29e - 3 6 . 17e - 3 7 . 04e - 3 8 . 82e - 3 1 . 06e - 2 3 . 178 - 3 
8 : 1 11 : 1 14 : 1 17 : 1 19 : 1 23 : 1 28 : 1 33 : 1 - 
Concentration 
Mol / min 
Molar ratio 
[ BS : B - CD ] 
30 
11 15 5 
4 . 36 
7 : 1 
( 12 ) to prevent the reagent stream reverse flow as a result of TABLE 2 
differential flow pressure in either of the feed lines . In one 
embodiment , the PTFE tubing was put in a water bath to The relationship between pump drive speed and flow rate giving rise to different butane sultone - ß - cyclodextrin 
maintain temperature at approximately 50 - 60° C . In another molar ratios - constant butane sultone flow rate . 
embodiment , the PTFE tubing was put in a water bath to 35 
maintain temperature at approximately 60 - 100° C . B - CD BS 
In a round bottom flask , a stock solution of B - CD in Drive speed ( rpm ) 
NaOH solution ( 4 ) was first prepared as follows : 15 g of Flow rate ( ml / min ) 0 . 99 1 . 35 0 . 45 
B - CD ( 1 . 32x10 - 2 mole ) was added with stirring to an Concentration 5 . 94 4 . 4 x 10 - 3 Mol . min x 10 - 4 aqueous solution composed of 6 g of NaOH in 30 ml water . 40 [ BS : B - CD ] Mole ratio 10 : 1 
This solution was maintained between 60 - 70° C . with a 
hotplate stirrer . 
At the given drive speeds , pump ( 8 ) was used to deliver er In addition , the effect of changing the amount of NaOH at 
stock B - CD solution into the CSTR ( 14 ) via a three way a given drive speed / BS : B - CD mole ratio was also carried 
connector ( 12 ) where the reaction initially takes place , while 45 out , thus obtaining a series of NaOH : CD mole ratios , as 
pump ( 10 ) was used to also deliver neat butane sultone ( 6 ) , shown in FIG . 4 . The crude reaction products were dialysed 
at ambient temperature , through the connector ( 12 ) into the and lyophilized to obtain the sulphobutyl ether of B - CD as 
CSTR ( 14 ) . However , in some embodiments , the neat sul a white solid intermediate for chemical analysis . The prod 
tone ( 6 ) can be heated to 60 - 90° C . The CSTR ( 14 ) con uct was analysed using capillary electrophoresis , mass spec 
tained two 10 ml chambers and was provided to increase the 50 trometry and HPLC to show the degree of substitution , 
residence time for the reaction to continue , having started in HPLC was carried out to show unreacted B - CD and levels of 
the connector ( 12 ) . In one embodiment , pump ( 8 ) was first BS residues were analysed by gas chromatography . The 
turned on to feed the B - CD until it reached the first chamber lyophilised product was weighed to give the yield . 
of the CSTR ( 14 ) , after which pump ( 10 ) was then turned on 
to feed the butane sultone into the CSTR ( 14 ) . However , in 55 Example 1 
another embodiment , pumps ( 8 , 10 ) are both activated at the 
same time in order to avoid pumping pure B - CD through the Referring to FIGS . 2 and 3 , there are shown embodiments 
system to produce higher than desirable unreacted precursor of the apparatus 2 for the continuous flow synthesis of 
that would ultimately need to be removed by downstream SBE - B - CD . Two reservoirs ( 4 ) , ( 6 ) are primed , the first 
processing . An internal vortex circulation was generated 60 reservoir ( 4 ) containing " activated ” B - cyclodextrin and 
within the continuous flowing reaction stream within the sodium hydroxide in an aqueous solution , and the second 
CSTR ( 14 ) , which ensured rapid mixing . Efficient stirring reservoir ( 6 ) containing pure 1 , 4 - butane sultone . A first 
appears to be very important to the success of the process . peristaltic pump ( 8 ) was turned on to feed the B - cyclodextrin 
The reaction solution was delivered via pumps ( 8 , 10 ) into and sodium hydroxide in aqueous solution through a three 
the CSTR ( 14 ) in a continuous manner . 65 way junction ( 12 ) with non - return valves . A second peri 
The PTFE tubing is about 30 cm in length and is not staltic pump ( 10 ) was turned on to feed the 1 , 4 - butane 
sufficient for the reaction to complete prior to entry into the sultone also through the junction ( 12 ) where it reacted with 
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the B - cyclodextrin . The stoichiometry of the reaction could which indicates equivalence of substitution envelope . Both 
be controlled by mixing the two reaction streams at differ plots show about 9 distinguishable peaks which correspond 
ential rates , and the ratio of B - cyclodextrin to sodium to the degree of substitution . 
hydroxide could be adjusted in the reservoir ( 4 ) prior to Referring to FIG . 8 , there is shown the electropherograms 
mixing with 1 , 4 - butane sultone . The amount of SBE - B - CD 5 for standard sample of Batch produced SBE - B - CD and 
produced in the process is therefore a function of pumping SBE - B - CD produced by continuous flow synthesis at a 6 : 8 
time , and not equipment scale . The residence time of the BS / CD drive speed at a given BS : CD mole ratio as shown 
reaction between the B - cyclodextrin / NaOH solution and in Table 1 . The two electropherograms show coincidence 
1 , 4 - butane sultone was increased by passing the mixture which indicates equivalence of substitution envelope . Both 
from the outlet of the three - way junction ( 12 ) to a holding 10 plots show about 9 distinguishable peaks which correspond to the degree of substitution . chamber / sight glass or continuous stirred tank reactor Referring to FIG . 9 , there is shown the electropherograms ( CSTR ) ( 14 ) where further reaction took place . The CSTR for standard sample of Batch produced SBE - B - CD and ( 14 ) could be replaced in whole or in part with a temperature SBE - B - CD produced by continuous flow synthesis at a 7 : 8 
controlled coiled tubing of sufficient length . This would 15 BS / CD drive speed and at given BS : CD mole ratio as shown 
provide appropriate level of turbulence and residence time in Table 1 . The electropherogram for the continuous flow 
for the coupling reaction to complete efficiently . shows an intense peak between 4 and 5 minutes , this peak 
The inventors ' primary focus was to study the complexity possibly indicating the presence of a reaction impurity . The 
of the sulphoalkylation reaction in the flow synthesis mode . BS : B - CD mole ratio indicates an excess of BS . 
It was therefore necessary to dialyse ( 18 ) the reaction 20 Referring to FIG . 10 , there is shown the electrophero 
effluent ( 16 ) , freeze dry it ( 20 ) and then analyse it ( 22 ) . grams for standard sample of Batch produced SBE - B - CD 
Under commercial conditions , the SBE - B - CD effluent ( 16 ) and SBE - B - CD produced by continuous flow synthesis at a 
leaving the CSTR ( 14 ) would be connected to the down - 8 : 8 BS / B - CD drive speed at given BS : CD mole ratio as 
stream processing elements , e . g . continuous dialysis , flow - shown in Table 1 . As can be seen , there are 10 peaks for the 
through depyrogenation columns and membrane pre - filters 25 CF method and only 9 peaks for the Batch method . The ( pore size 0 . 22 um or greater ) prior to dynamic active number of peaks is indicative of the degree of substitution 
pharmaceutical ingredient addition processes described in for the derivatives . 
FIG . 23 . The SBE - B - CD produced has been analysed by Referring to FIG . 11 , there is shown the electrophero 
mass spectrometry , capillary electrophoresis for comparison grams for standard sample of Batch produced SBE - B - CD 
with the patent literature . The other processing simply 30 and SBE - B - CD produced by continuous flow synthesis at a 
becomes an engineering problem as it involves mixing or 10 : 8 BS / CD drive speed at given BS : CD mole ratio as 
purification of aqueous SBE - B - CD or SBE - B - CD - drug com shown in Table 1 . The electropherogram for the continuous 
plex solutions . flow shows an intense peak between 4 and 5 minutes , again 
Results this peak possibly indicating the presence of a reaction 
Referring to FIGS . 5 - 20 , there are shown electrophero - 35 impurity . The BS : B - CD mole ratio indicates an excess of BS . 
grams for the standard batch ( standard ) and continuous flow Referring to FIG . 12 , there is shown the electrophero 
( CF ) synthesis of SBE - B - CD at the different BS : B - CD grams for standard sample of Batch produced SBE - B - CD 
molar ratios resulting from differential pump speeds at a and SBE - B - CD produced by continuous flow synthesis at a 
constant B - CD : sodium hydroxide mass ratio , or at different 12 : 8 BS / CD drive speed at given BS : CD mole ratio as 
B - CD : sodium hydroxide mass ratios for two different BS : B - 40 shown in Table 1 . The electropherogram for the continuous 
CD molar ratios as indicated . The standard curve ( solid line ) flow also shows an intense peak between 4 and 5 minutes , 
corresponds to the known batch manufacture method of this peak possibly indicating the presence of a reaction 
SBE - B - CD , as described in U . S . Pat . No . 6 , 153 , 746 ( Shah et impurity . The BS : B - CD mole ratio indicates an excess of BS . 
al , 2000 ) . The dotted trace in each graph however is for an Referring to FIG . 13 , there is shown the electrophero 
SBE - B - CD sample produced by a continuous flow ( CF ) 45 grams batch manufactured SBE - B - CD as the solid line and 
synthesis process according to the invention . SBE - B - CD manufactured by the continuous flow process 
Referring to FIG . 5 , there is shown the electropherograms with a 7 : 1 butane sultone to B - cyclodextrin molar ratio as the 
for SBE - B - CD produced using the known batch method dotted line . The sodium hydroxide to B - CD molar ratio is 
compared to continuous flow ( CF ) with a 1 , 4 - Butane Sul - 6 : 1 . As can be seen , coincidence of the two electrophero 
tone ( BS ) : Beta cyclodextrin ( B - CD ) drive speed of 3 : 8 and 50 grams indicates an equivalent Substitution Envelope ' , i . e . 
with a given BS : CD mole ratio as shown in Table 1 . As can degree of substitution distribution . However , it is remark 
be seen , there are 10 peaks for the CF method and only 9 able that the continuous flow synthesis process of the 
peaks for the Batch method . The number of peaks is invention requires less than 50 % of the sodium hydroxide 
indicative of the degree of substitution for the derivatives . that is used in the prior art batch process ( Stella et al , 1994 ) , 
Referring to FIG . 6 , there is shown the electropherograms 55 and a 7 : 1 molar ratio of 1 , 4 - butane sultone to ß - cyclodextrin 
for standard sample of Batch produced SBE - B - CD and instead of the 10 : 1 used by the prior art method . This finding 
SBE - B - CD produced by continuous flow synthesis at a 4 : 8 was completely unexpected , given that the inventors ' expec 
BS / CD drive speed and therefore a given BS : CD mole ratio tation was at best an equivalent synthetic efficiency . 
as shown in Table 1 . As can be seen , there are 10 peaks for Although the inventors do not wish to be bound by any 
the CF method and only 9 peaks for the Batch method . The 60 theory , it would appear that the shielding of sodium hydrox 
number of peaks is indicative of the degree of substitution ide from 1 , 4 - butane sultone up to the point where the 
for the derivatives . reaction streams mix and the reaction takes place allows for 
Referring to FIG . 7 , there is shown the electropherograms an efficient activation of ß - cyclodextrin hydroxyl groups at 
for standard sample of Batch produced SBE - B - CD and the point of the reaction with minimal degradation of 
SBE - B - CD produced by continuous flow synthesis at a 5 : 8 65 1 , 4 - butane sultone to low molecular weight by - products . In 
BS / CD drive speed , at a given BS : CD mole ratio as shown short , using the continuous flow method of the invention , 
in Table 1 . The two electropherograms show coincidence 1 , 4 - butane sultone can react with B - cyclodextrin more effi 
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ciently and completely to generate higher degrees of sub sodium hydroxide compared to the amount used in the batch 
stitution with more efficient use of the starting materials . process ( Stella et al , 1994 ) , and an increase from 7 : 1 to 10 : 1 
The average degree of substitution ( ADS ) can be readily molar ratio of 1 , 4 - butane sultone to B - cyclodextrin . As can 
determined using the following formula taken from U . S . Pat . be seen , there are 10 peaks for the CF method and only 9 
No . 7 , 635 , 77B2 ( Antle , 2009 ) : 5 peaks for the batch method . The number of peaks is indica 
tive of the distribution of degree of substitution for the 
ADS = E ( ( PAC ) x ( MT ) / SCAX100 / 100 derivatives . However , the electropherogram for the continu 
Where PAC refers to the peak area count ; MT refers to the ous flow shows an intense peak at 5 minutes this possibly 
migration time ; and SCA refers to the summation of cor - indicates the presence of a reaction impurity . 10 
rected area . Referring to FIG . 18 , there is shown the electrophero To test this hypothesis further , the inventors attempted to grams for standard sample of Batch produced SBE - B - CD increase the ratio of sodium hydroxide to B - cyclodextrin , and SBE - B - CD sample produced by continuous flow syn 
and the results are shown in FIGS . 14 - 20 . In the prior art thesis . The continuous flow uses only 75 % sodium hydrox batch process , according to Shah , this would have no 15 ide compared to the amount used in the batch process ( Stella beneficial effect on the average degree of substitution or the 
et al , 1994 ) , and an increase from 7 : 1 to 10 : 1 molar ratio of distribution of low degree of substitution species , i . e . a 1 , 4 - butane sultone to B - cyclodextrin . The electropherogram change in the substitution envelope , because the sodium 
hydroxide would simply destroy the 1 , 4 - butane sultone for the continuous flow shows a positive shift of the sub 
before reaction with the hydroxyls could take place . In 20 stitution envelope and change in the modal degree of sub 
essence , there is a kinetic limit to the degree of substitution stitution from 6 min to 8 min , this indicates a higher 
rocessing conditions . Shah exploits this to average degree of substitution . 
maximise the degree of substitution and reduce the residual Referring to FIG . 19 , there is shown there is shown the 
concentration of reactants . 25 electropherograms for standard sample of Batch produced 
Referring to FIG . 14 , there is shown the electrophero - SBE - B - CD and SBE - B - CD sample produced by continuous 
grams for standard sample of Batch produced SBE - ß - CD flow synthesis . The continuous flow uses the same amount 
and SBE - B - CD sample produced by continuous flow syn of sodium hydroxide compared to the amount used in the 
thesis . As can be seen , the continuous flow uses only 75 % batch process ( Stella et al , 1994 ) , and a 10 : 1 molar ratio of 
sodium hydroxide compared to the amount used in the batch 30 1 , 4 - butane sultone to B - cyclodextrin , identical conditions process ( Stella et al , 1994 ) , and a 7 : 1 molar ratio of used by ( Stella et al , 1994 ) . The electropherogram for the 1 , 4 - butane sultone to ß - cyclodextrin instead of the 10 : 1 used continuous flow shows a positive shift of the substitution by the prior art method . The electropherogram for the 
envelope and a change in the modal degree of substitution continuous flow shows a positive shift of the substitution z 35 from 6 min to 8 min , a smaller population of lower degrees envelope and change in the modal degree of substitution 
from ~ 6 min to 8 min , and this indicates a higher average of substitution ( migration time range 2 - 7 minutes ) and this 
degree of substitution can be achieved more economically . indicates a higher degree of substitution . Comparing the 
Referring to FIG . 15 , there is shown there is shown the electropherogram at identical mole ratios of the material 
electropherograms for standard sample of Batch produced 40 used , the flow method results in species with higher degrees 
SBE - B - CD and SBE - B - CD sample produced by continuous of substitution suggesting a more efficient and hence a more 
flow synthesis . As can be seen , the continuous flow uses the economical production of cyclodextrin . 
same amount of sodium hydroxide compared to the amount 
used in the batch process ( Stella et al , 1994 ) , and a 7 : 1 molar Referring to FIG . 20 , there is shown an electropherogram 
ratio of 1 , 4 - butane sultone to B - cyclodextrin instead of the 45 01 us of batch - produced ( Shah et al , 2000 ) and continuous flow 10 : 1 used by the prior art method The electropherogram for produced standard SBE - B - CD . The continuous process used 
the continuous flow shows a positive shift of the substitution to produce the material shown in FIG . 20 used 25 % more 
envelope and a further change in the modal degree of sodium hydroxide than the batch process ( Stella et al , 1994 ) , 
substitution from 6 min to 8 . 5 min , and this indicates a with an increase in the molar ratio of 1 , 4 - butane sultone to 
higher average degree of substitution . 50 B - cyclodextrin from 7 : 1 to 10 : 1 . Hence , the material pro 
Referring to FIG . 16 , there is shown there is shown the duced by flow synthesis is novel and demonstrates a positive 
electropherograms for standard sample of Batch produced skew in the Substitution Envelope with a smaller population 
SBE - B - CD and SBE - B - CD sample produced by continuous of lower degrees of substitution ( migration time range 2 - 7 
flow synthesis . As can be seen , the continuous flow uses minutes ) and the modal degree of substitution changing 
25 % more sodium hydroxide compared to the amount used 55 from ~ 6 minutes to ~ 8 minutes . It is concluded therefore that 
in the batch process ( Stella et al , 1994 ) , and a 7 : 1 molar ratio the continuous flow method of the invention results in an 
of 1 , 4 - butane sultone to ß - cyclodextrin instead of the 10 : 1 increase in efficiency ( more efficient activation of ß - cyclo 
used by the prior art method . The electropherogram for the dextrin hydroxyl groups by sodium hydroxide ; less con 
continuous flow shows a positive shift of the substitution sumption of 1 . 4 - butane sultone ) resulting in a higher degree 
envelope and further change in the modal degree of substi - 60 of substitution 
tution from ~ 6 min to 8 min , very small population of lower 
degrees of substitution ( migration times ~ 2 - 7 min ) , and this A number of experiments were carried out , in order to 
indicates a higher degree of substitution . fully explore the effect of changing the B - CD : sodium 
Referring to FIG . 17 there is shown the electrophero - hydroxide mass ratio , by altering the sodium hydroxide 
grams for standard sample of Batch produced SBE - B - CD 65 content between 0 % to 200 % compared to the amount used 
and SBE - B - CD sample produced by continuous flow syn - in the batch process ( Stella et al , 1994 ) . The results of this 
thesis . As can be seen , the continuous flow uses only 50 % investigation have been highlighted in Table 3 . 
US 10 , 239 , 961 B2 
15 16 
TABLE 3 
The effect of changing the NaOH : B - CD mole ratio by the changing the NaOH content ; 100 % nominal 
sodium hydroxide is equivalent to the base content used in U . S . Pat . No . 5 , 376 , 645 ( Stella et al , 1994 ) . 
Percentage 
of NaOH NaOH : B - CD 
mole ratio % Observation ( when reacted with butane sultone ) 
2 : 1 
3 : 1 
5 : 1 
6 : 1 
75 9 : 1 
100 11 : 1 
Very turbid unstable solution with solid white B - CD 
precipitating out of solution 
Less turbid immiscible solution with two layers 
formed . 
Less turbid immiscible solution with two layers 
formed . 
Less turbid immiscible solution with tiny butane 
sultone particles suspended 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution , solution 
becoming more viscous 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution , solution 
becoming more viscous 
Butane sultone reacts with the B - CD solution forming 
a single phase homogenous solution , solution 
becoming more viscous 
Butane sultone reacts with the B - CD solution forming 
a thick viscous paste 
125 14 : 1 
150 17 : 1 
160 18 : 1 
175 20 : 1 
200 22 : 1 
In the absence of base ( i . e . 0 % NaOH ) , B - CD was The manufacturing process is as follows : 
insoluble and therefore did not react with BS thus precipi 1 . Add SBE - B - CD to 80 % of the final volume of Water for 
tating out . At 20 - 40 % NaOH , the two phases would not mix , Injections with constant stirring until dissolved ; 
and B - CD could not react fully with BS . At 150 % NaOH , the 33 2 . Add the voriconazole and stir until dissolved ; dialysed product could not be freeze - dried , and also the 3 . Make up the solution to its final volume ( hence dialysis membrane was damaged by unreacted butane sul concentration ) with the remaining Water for Injections ; tone and the very basic condition arising from high concen 4 . Filter the resulting solution through a sterilizing filter trations of sodium hydroxide , hence causing weakening and 
damaging the membrane . At 200 % sodium hydroxide , a 40 ( 0 . 22 um pore size ) into a sterile container in a suitably validated GMP manufacturing area ; viscous paste was formed that prevented pumping of the 
reaction products . Hence , within the geometry of the appa 5 . Fill into 20 ml injection vials and stopper , and 
ratus used , 50 - 125 % compared to the amount used in the 6 . Freeze - dry the product , stopper , over - cap and label . 
batch process ( Stella et al , 1994 ) , would allow SBE - B - CD to The goal of this work was to try and develop innovative 
be manufactured using flow chemistry . 45 approaches to the manufacture and application of SBE - B 
CD in the pharmaceutical industry . As can be seen from FIG . Example 2 23 , use of the method of the invention means that three steps 
shown in FIG . 22 can be omitted . It is evident on inspection The first application of SB - B - CD in an injectable phar of FIG . 23 that by combining the two processes , three maceutical drug product ( i . e . voriconazole ) is described in 50 product ( 1 . e . Voriconazole ) is described in 50 commercial advantages arise : the 2003 Pfizer patent , U . S . Pat . No . 6 , 632 , 803B1 . The 1 . It becomes unnecessary to transport SBE - B - CD from formulation of an injectable form of voriconazole is the fine chemical manufacturer to the customer . This described in Table 4 . 
would also include warehousing , etc . 
TABLE 4 2 . SBECD could be manufactured on a just - in - time , just - enough basis . 
Formulation of an injectable form of voriconazole using the 3 . One of the two expensive and time - consuming freeze SBE - B - CD platform drying or spray drying process steps could be avoided . 
Concentration 
in mg / ml in 1 ml Example 3 
Ingredient or of injectable 
Excipient Purpose drug product 
The inventors have obtained Vapourtec flow chemistry 
Voriconazole Active Pharmaceutical 10 . 0 equipment as illustrated in FIG . 21 , which is more suited to Ingredient 
commercial manufacture than the ‘ hand built ' reactors used SBE - B - CD Solubilising Agent 160 . 0 
Water for Injections Solvent vehicle To 1 . 0 ml 65 to date . It was necessary to optimise the reaction to meet the 
specification criteria set out in Shah ' s patent with respect to 
residual B - cyclodextrin and 1 , 4 - butane sultone . In addition , 
60 
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the SBE - B - CD effluent stream was conditioned to meet the trin - sodium hydroxide streams may become miscible ; mis 
requirements of pharmacopoeial Water for Injections mono cibility is generally considered to be an important process 
graphs . condition of flow chemistry processing . Judging by the 
Average Degrees of Substitution achieved by prior art meth Example 4 5 ods , the goal of miscibility appears to have been achieved at 
the expense of butane sultone stability which has led to very 
As aqueous solutions of ß - CD are intrinsically pyrogenic , low Average Degrees of Substitution . 
the batch process requires depyrogenation as part of the The method of the invention however involves carefully downstream purification . Using this CF manufacturing reacting sodium hydroxide with ß - cyclodextrin to activate it 
method , it is possible to depyrogenate the system in reser - 10 in a in advance of a two - phase continuous flow reaction , and this 
voir ( 4 ) prior to reaction than post reaction . is important in creating a highly efficient reaction and a Summary controllable Average Degree of Substitution in a small The results described herein demonstrated that the con footprint . The activation process must be conducted at tinuous flow process chemistry is a more efficient way of 
elevated temperature ( 65 - 100° C . ) and for a specified time producing SBECD and this is reflected in : 
( i ) the average degree of substitution , after the ß - cyclodextrin has dissolved in the aqueous sodium ( ii ) the low frequency of low degrees of substituted hydroxide solution . The activation process has typically 
SBECD species ; taken 30 minutes at this scale ; the major indicator of ( iii ) production of SBECD with reduced quantities of completion is the colour change which could be measured 
starting materials ; 20 colourimetrically . ( iv ) the production of material , free from significant It is highly unlikely that this time and temperature depen 
impurities , allowing avoidance of quenching and inten - dent activation could be achieved in any prior art batch or 
sive downstream processing . continuous flow methods . Whilst the reaction procedure 
The frequency of low degree of substituted SBECD employs a CSTR , it is a surrogate for the use of a flow 
species using the prior art batch reaction is much higher than 25 reactor with efficient mixing and of suitable length to allow 
with using the continuous flow chemistry of the invention . the reaction to complete within the reactor tubing . The 
The continuous flow method of the invention enables a activation of ß - cyclodextrin is an important process param 
greater reaction efficiency . The novel species produced by eter prior to reaction and this must continue irrespective of 
the continuous flow process have a higher degree of substi - the reactor architecture . 
tution with a tighter distribution of substitution , as well as a 30 
higher average degree of substitution per se . Example 6 
Example 5 Analytical Methodology for High Degree of 
Substitution SBECD Species 
The CSTR - Based Manufacturing Process 35 
The original work described herein was based on the 
The aim of this work was to develop a continuous capillary electrophoresis method for sulphobutylether ß - cy 
manufacturing process for the manufacture of sulphobuty - clodextrin described in the United States Pharmacopoeia 
lether B - cyclodextrin . It is known that mixing the B - cyclo - 35 / National Formulary 30 ( USP35 / NF30 ) . The output of the 
dextrin and sodium hydroxide in a controlled way is impor - 40 analysis , the so - called electropherogram , is shown in FIGS . 
tant to the success of the method of the invention . Firstly , it 5 - 20 . 
is important that both the aqueous , basified ( i . e . activated ) It can be seen that , whilst a qualitative idea of the 
B - cyclodextrin solution ( 4 ) is heated within the range of substitution pattern is possible , it is not easy to integrate the 
60 - 90° C . prior to mixing . Secondly , as B - cyclodextrin is areas under the peaks reliably due to the shifting baseline . It 
added to the sodium hydroxide solution , a three stage 45 is also evident from FIGS . 14 - 16 and 18 - 20 that peak 
“ activation process occurs : resolution deteriorates with increasing substitution . Peaks 
1 ) Firstly , it takes a finite time to add the B - cyclodextrin appear to merge after approximately 8 minutes into the run 
into the reservoir vessel containing aqueous sodium which makes it difficult to quantify the pattern of substitu hydroxide . tion . Furthermore , the true nature of the substitution enve 
2 ) Next , the B - cyclodextrin dissolves in the sodium 50 lope could not be clearly understood . 
hydroxide solution . Alternative methods have been proposed for the analysis 
3 ) Finally , and more significantly , an initial solution straw of cyclodextrin derivatives using high performance liquid 
colouration progressively “ deepens ' which is consid chromatography ( I . Szeman 2006 ) . This has been recently 
ered to be a sign of completion of the activation of the updated and applied to sulphobutylether B - cyclodextrin ( J . 
B - cyclodextrin by sodium hydroxide . With the deep 55 Szeman 2012 ) . The method is based on a specialised ion 
colouration present , and the reagents at the specified exchange HPLC column , CD - Screen - DAP , where a bonded 
temperature , mixing then proceeds . dimethylamino phenyl function includes in the eluting sul 
The reaction proceeds in a continuous manner , i . e . once phobutylether B - cyclodextrin to improve the selectivity of 
the pumps ( 8 , 10 ) have started they are not switched off until the analytical method . 
completion of the reaction . It is now generally considered 60 High performance liquid chromatography with evapora 
that the main reaction takes place in the first CSTR chamber tive light scattering detection ( ELSD ) is used for the sepa 
( 14 ) . The reaction takes place at a low temperature ( 65 - 100° r ation of sulphobutylether ß - cyclodextrin into its substituted 
C . ) and atmospheric pressure . The CSTR - process handles constituents in order to determine the average degree of 
the B - cyclodextrin - sodium hydroxide solutions and butane substitution . Identification of each substituted cyclodextrin 
sultone as an immiscible , two phase system . 65 is determined by comparing the retention times of the 
It is known that some prior art methods create the con - standard , produced by the method described in U . S . Pat . No . 
ditions where butane sultone and the aqueous ß - cyclodex - 6 , 153 , 746 ( Shah , 2000 ) , and tested according to the methods 
10 
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described in USP35 / NF30 with that of a material produced The Individual Degree of Substitution ( IDS » ) is calculated 
using the processing method described herein . using the following formula : 
The chromatographic conditions are summarised as fol IDS , = ( PA . , / EPA ) x100 lows : 
Reagents where EPA = 2PAz + PA2 + 1 . . . PAH 
1 . Acetonitrile , HPLC grade n = Substitution Number 
2 . 0 . 5 % triethylamine - acetic acid buffer , pH = 5 . 0 PA = Peak area PAq = Peak area corresponding to lowest degree of substi 
tution seen on the chromatogram 
Chromatographic Conditions PAJ Peak area corresponding to highest degree of sub 
stitution seen on the chromatogram 
Instrument : Agilent 1100 series or equivalent HPLC instru These data can be used to describe an ‘ Envelope of 
ment 
Software : OpenLAB or similar system Substitution ' which is used as the basis of a specification 
Column : CD - Screen - DAP , 3 um , 150 x 4 . 0 mm , 15 element in USP35 / NF30 , where each IDS , should fall within 
CDS - DAP - 1504 - 03 the series of specified Proven Acceptable Ranges thus defin Column temperature : 25° C . + 1° C . ing the ‘ Substitution Envelope ' . Mobile phase A ( MPA ) : 0 . 5 % triethylamine - acetic acid buffer , pH = 5 
Mobile phase B ( MPB ) : acetonitrile , HPLC grade The Individual Degree of Substitution metrics are then 
Flow rate : 1 . 0 ml / min used to calculate the Average Degree of Substitution as 
Gradient Ratio Time ( min ) 6 15 20 follows : MPA % ) 100 50 50 
MPB ( % ) 0 50 50 ADS = E ( IDS xn ) / 100 ( 3 ) Detection : ELSD 
Injection volume : 5 ul Table 1 shows data for the chromatogram shown in FIG . 
Concentration : 10 mg / ml 25 . This can now be processed using Equations 1 - 3 as 
Acquisition time : 15 minutes with post - time of 5 minutes 25 follows : Needle wash : none 
TABLE 1 
ELSD Conditions 30 
Integration table of the chromatogram of sulphobutylether 
B - cyclodextrin produced by the method of the invention . 
Reaction conditions correspond to those used to generate 
FIG . 20 HPLC conditions are based on a gradient separation 
with a CD - Screen - DAP column and ELSD detection 
Instrument : Alltech ELSD 2000 or equivalent ELSD instru 
ment 
115° C . 
3 . 2 L / min 
Tube temperature : 
Gas flow ( nitrogen ) : 
Gain : 
Impactor : 
Substitution 
Number : 2 Retention Time : Peak Area : 
Off 35 
Ovauw 
5 . 77 
6 . 29 
6 . 67 
6 . 98 
7 . 33 
7 . 63 
7 . 99 
8 . 31 
8 . 58 
8 . 90 
9 . 28 
0 . 271 
0 . 507 
1 . 455 
3 . 142 
5 . 221 
13 . 283 
24 . 842 
46 . 056 
53 . 920 
39 . 220 
16 . 570 
10 
Individual Degree of Substitution — Specimen Calcula 
EPA = EPA2 + PA2 + 1 . . . PAHI 
EPA = PA3 + PA4 + PAF + PAG + PA7 + PA9 + PA9 + PA10 + 
PA11 + PA12 + PA13 
A typical chromatogram for the standard material pro 
duced using a prior art batch method described in U . S . Pat . 
No . 6 , 153 , 746 ( Shah , 2000 ) is shown in FIG . 24 . Upon 40 
further examination of FIG . 24 , it can be seen that material 
produced by the prior art process has a range of substitution 
from Degree of Substitution 2 to 10 . The Average Degree of 
Substitution is 6 . 6 . 
The chromatogram for the sulphobutylether B - cyclodex - 45 
trin produced using the method of the invention and corre - 
sponding to FIG . 20 is shown in FIG . 25 . It is readily seen 
that a stable baseline is generated facilitating integration and 
subsequent processing of the signal . FIG . 25 indicates that 
material produced using the invention has a range of sub - 50 
stitution from Degree of Substitution 3 to 13 . The Average 
Degree of Substitution is 10 . 4 , as described below . 
In addition to producing sulphobutylether ß - cyclodextrin 
with a higher Average Degree of Substitution , the method of 
the invention , under these conditions , does not produce any » 
detectable di - substituted sulphobutylether B - cyclodextrin 
and produces significant quantities of Degree of Substitution 
11 - 13 not detected in the U . S . Pat . No . 6 , 153 , 746 ( Shah , 
2000 ) material . 
The inventors also have the corresponding HPLC traces 
corresponding to the electropherograms in FIGS . 12 to 20 . 
The power of the technique gives access to descriptive 
statistics . 
The Average Degree of Substitution is discussed herein 65 
using the standard method of calculation . This method was 
modified for use with HPLC outputs and is explained below . 
EPA = 0 . 271 + 0 . 507 + 1 . 455 + 3 . 142 + 5 . 221 + 13 . 283 + 
24 . 842 + 46 . 056 + 53 . 920 + 39 . 220 + 16 . 570 
SPA = 204 . 487 
IDS , = ( PA , / EPA ) x100 
60 IDSz = ( PA2 / EPA ) x100 = ( 0 . 271 / 204 . 487 ) x 
100 = 0 . 132527 
IDS4 = ( PAL / EPA ) x100 = ( 0 . 507 / 204 . 487 ) x 
100 = 0 . 247938 
IDS5 = ( PA3 / EPA ) x100 = ( 1 . 455 / 204 . 487 ) x 
100 = 0 . 711537 
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IDS6 = ( PAG / EPA ) x100 = ( 3 . 142 / 204 . 487 ) x 
100 = 1 . 536528 The material described in FIG . 25 therefore has an aver age degree of substitution of 10 . 4 , which is substantially 
higher than material produced by batch manufacture or fully 
continuous flow process . IDS7 = ( PA7 / EPA ) x100 = ( 5 . 221 / 204 . 487 ) x 100 = 2 . 553219 
IDS8 = ( PAG / EPA ) x100 = ( 13 . 283 / 204 . 487 ) x 
100 = 6 . 495767 
Example 7 
IDS , = ( PA , EPA ) x100 = ( 24 . 842 / 204 . 487 ) 
100 = 12 . 14845 10 
The Manipulation of Average Degree of 
Substitution Using Sodium Hydroxide 
IDS10 = ( PA10 / 2PA ) x100 = ( 46 . 056 / 204 . 487 ) x 
100 = 22 . 5277 
IDS11 = ( PA1 / EPA ) x100 = ( 53 . 920 / 204 . 487 ) x 
100 = 26 . 36842 
IDS12 = ( PA12 / EPA ) x100 = ( 39 . 220 / 204 . 487 ) x 
100 = 19 . 1797 
IDS13 = ( PA13 / EPA ) x100 = ( 16 . 570 / 204 . 487 ) x 
100 = 8 . 103205 
Average Degree of Substitution Specimen Calculation 
ADS = X ( IDSnxsubstitution number ) / 100 
n = substitution number 
IDS , substitution number 
The samples of sulphobutylether ß - cyclodextrin that have 
been produced have now been reanalysed by HPLC . The 
15 data has been processed to generate the Average Degrees of 
Substitution . The table shown in FIG . 26 shows a summary 
of the data adding the Average Degree of Substitution data 
and dispersion data . 
In general , it can be seen from the Table in FIG . 26 that 
an increase in the content of sodium hydroxide will increase 
the Average Degree of Substitution of sulphobutylether 
B - cyclodextrin . Furthermore , the more extreme CSTR reac 
tions produce material with Average Degree of Substitution 
25 at levels not previously seen using batch or continuous flow 
reactions . The higher Average Degree of Substitution arises 
due to the presence of highly substituted species with an 
Individual Degree of Substitution in excess of 10 . 
The table shown in FIG . 27 describes an attempt to 
30 produce material compliant with the USP35 / NF30 mono 
graph with the use of more moderate reaction conditions . 
Analysis indicated that the IDS , ' envelope ' present in the 
CSTR 10 : 1 butane sultone : ß - cyclodextrin molar ratio and a 
6 : 1 Sodium hydroxide to B - cyclodextrin molar ratio reaction 
produced the nearest match . It can be seen that , using the 
HPLC method , the U . S . Pat . No . 6 , 153 , 746 ( Shah , 2000 ) 
material broadly complies with the specification . The mate 
rial produced by the CSTR method is less compliant due to 
40 a more symmetrical distribution of IDS .. . Whilst compliant 
material has yet to be produced , the ability to control the 
process with respect to stoichiometry indicates that , with 
further process refinement , this should be possible . 
IDS2x3 = 0 . 132527x3 = 0 . 397580 
IDS4x4 = 0 . 247938x4 = 0 . 991750 
IDS X5 = 0 . 711537x5 = 3 . 557683 
35 
IDS6 * 6 = 1 . 536528x6 = 9 . 219168 
IDS - x7 = 2 . 553219x7 = 17 . 872530 
IDS3 * 8 = 6 . 495767x8 = 51 . 966140 
IDS , X9 = 12 . 14845x9 = 109 . 336046 
IDS , 0x10 = 22 . 5277x10 = 225 . 227032 45 Example 8 
IDS 4x11 = 26 . 36842x11 = 290 . 052668 
IDS12 12 = 19 . 1797x12 = 230 . 156440 Novelty of SBE - B - CD Prepared Using the Method of the Invention 
50 
IDS 2x13 = 8 . 103205x13 = 105 . 341660 
E ( IDS , xsubstitution number ) = ( IDS3X3 ) + ( IDS4X4 ) + ( IDS5 * 5 ) + ( IDS & * 6 ) + ( IDS 7x7 ) + ( IDS , * 8 ) + ( IDS , X9 ) + ( IDS10x10 ) + ( IDS 11x11 ) + ( IDS 12x12 ) + ( IDS 13x13 ) 55 
X ( IDS , substitution number ) = 0 . 397580 + 0 . 991750 + 
3 . 557683 + 9 . 219168 + 17 . 872530 + 51 . 966140 + 
109 . 336046 + 225 . 227032 + 290 . 052668 + 
230 . 156440 + 105 . 341660 
Historically , the number of pendant sulphobutyl groups 
on the cyclodextrin determines the Individual Degree of 
Substitution metric and the Substitution Envelope . The 
weighted average of the abundance of each species gives 
rise to the Average Degree of Substitution metric . There are 
three possibilities for defining the novelty of the SBE - B - CD 
prepared using the method of the invention : 
a ) Substitution 
60 What is really important , chemically , is the number of 
cyclodextrin rings available to form inclusion complexes 
with drugs , because this is what makes the cyclodextrin 
work . Whilst the parent beta cyclodextrin gives the greatest 
number of rings for a given molecular mass , it is believed to 
65 be nephrotoxic and this makes substitution necessary . It is 
known that increasing the degree of substitution increases 
the aqueous solubility of the cyclodextrin and high solubility 
X ( IDS , xsubstitution number ) = 1044 . 118697 
ADS = X ( IDS , substitution number ) 
100 = 1044 . 118697 / 100 = 10 . 44 
Average Degree of Substitution = 10 . 4 
23 
US 10 , 239 , 961 B2 
24 
of the cyclodextrin is a pre - requisite to achieving a high b ) Molecular Weight 
payload drug solubility . The following table summarises This is the first report of a derivatised species with a 
substitution molecular mass ratios : molecular weight in excess of 2486 . 68 Dalton or within the 
range 2621 . 85 - 2892 . 19 . Referring to FIG . 29 , there is shown 
- 5 the relationship between individual degree of substitution 
Beta Molecular Butane Mo - Sub and molecular weight . cyclo Weight sultons lecular stitution 
dextrin After Group Weight Molecular Molecular weight is believed to be an alias for Individual 
Molecular Proton Proton Con - for Mass Degree of Substitution and so the Substitution Molecular IDS Weight Loss Loss tribution IDS Fraction Mass Fraction ( SMF ) may be the better choice . 10 1134 . 98 - 1 1133 . 98 136 . 17 1270 . 15 0 . 11 c ) Substitution Envelope 1134 . 98 1132 . 98 272 . 34 1405 . 32 0 . 19 
3 1134 . 98 - 3 When considering Column 2 of FIG . 27 , it is possible to 1131 . 98 408 . 51 1540 . 49 0 . 26 
define a novel peak area limit as follows : WNE - 2 
USP - NF USP - NF 
Peak Area Peak Area 
Percentage Percentage 
IDSn Lower Limit Upper Limit 
Novel Novel 
Peak Area Peak Area 
Percentage Percentage 
Lower Limit Upper Limit 
CSTR 
10 : 1 and 
+ 25 % Range Shah Range 
OOONO AWNA
0 . 00 
0 . 00 
0 . 50 
2 . 00 
10 . 00 
15 . 00 
20 . 00 
10 . 00 
2 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 30 
0 . 90 
5 . 00 
10 . 00 
20 . 00 
25 . 00 
30 . 00 
25 . 00 
12 . 00 
4 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 30 
0 . 90 
4 . 50 
8 . 00 
10 . 00 
10 . 00 
10 . 00 
15 . 00 
10 . 00 
4 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 13 
0 . 88 
4 . 91 
14 . 61 
25 . 45 
29 . 50 
19 . 01 
4 . 99 
0 . 51 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 50 
0 . 50 
0 . 50 
2 . 00 
10 . 00 
15 . 00 
20 . 00 
10 . 00 
2 . 00 
0 . 00 
0 . 00 
0 . 00 
0 . 30 
0 . 90 
5 . 00 
5 . 00 
5 . 00 
10 . 00 
20 . 00 
25 . 00 
30 . 00 
25 . 00 
12 . 00 
4 . 00 
0 . 00 
0 . 00 
0 . 30 
0 . 90 
4 . 50 
4 . 50 
4 . 50 
8 . 00 
10 . 00 
10 . 00 
10 . 00 
15 . 00 
10 . 00 
4 . 00 
0 . 00 
0 . 00 
0 . 10 
0 . 20 
0 . 70 
1 . 50 
2 . 60 
6 . 50 
12 . 10 
22 . 50 
26 . 40 
19 . 20 
8 . 10 
0 . 00 
11 
13 
14 
Group 
4 
- 9 
- 10 
12 
- continued The USP - NF Peak Area Percentage describes a series of 
Proven Acceptable Ranges for an upper and lower distribu 
Beta Molecular Butane Mo Sub - 35 tion of IDSn in which a ' Substitution Envelope ' resides . 
cyclo Weight sultons lecular stitution With a shift in IDSn to higher values using the process of the dextrin After Weight Molecular 
Molecular Proton Proton Con for Mass invention , it is possible to shift the envelope . As shown in 
IDS Weight Loss Loss tribution IDS Fraction FIG . 27 , it is possible to ' de - tune the process of the 
invention to broadly comply with the USP - NF Envelope , 1134 . 98 1130 . 98 544 . 68 1675 . 66 0 . 32 
1134 . 98 1129 . 98 680 . 85 1810 . 83 0 . 37 40 and this is not possible using the fully batch or fully 
1134 . 98 1128 . 98 817 . 02 1946 . 00 0 . 42 continuous processes described in the prior art . 
1134 . 98 1127 . 98 953 . 19 2081 . 17 0 . 45 Summary 1134 . 98 - 8 1126 . 98 1089 . 36 2216 . 34 0 . 49 
1134 . 98 1125 . 98 2351 . 51 0 . 52 Using a novel , improved HPLC analytical method , the 
1134 . 98 1124 . 98 1361 . 70 2486 . 68 0 . 54 45 inventors have validated their earlier observations described 11 1134 . 98 - 11 1123 . 98 1497 . 87 2621 . 85 0 . 57 
1134 . 98 - 12 1122 . 98 1634 . 04 2757 . 02 0 . 59 herein . The technique has allowed them to produce descrip 
13 1134 . 98 - 13 1121 . 98 1770 . 21 2892 . 19 0 . 61 tive statistics for high degree of substitution material . The 
sulphobutylether ß - cyclodextrin composition , produced by The molecular mass of beta cyclodextrin is 1134 . 98 
Dalton . To create a mono - substituted beta cyclodextrin , a 50 me 50 the CSTR process according to the invention described 
proton is removed , and replaced with a linear butane sultone herein , is novel in two respects : ( i ) it has an unprecedented 
function with a molecular mass of 136 . 17 Dalton . The high average degree of substitution ; and ( ii ) the existence of resulting molecular mass of individual degree of substitution ( IDS ) , where n = 1 is 1270 . 15 Dalton . If one considers the highly substituted species with IDS , higher than 10 . The 
mass associated with the cyclodextrin ring as a fraction of 55 CSTR process depends upon pre - activation of the B - cyclo the total mass , it is possible to calculate a Substitution 55 
Molecular Mass Fraction . This means that ii % of the mass dextrin feedstock by sodium hydroxide where the extent of 
is associated with the substituent functions ( or 89 % is activation determines the Average Degree of Substitution . 
associated with the cyclodextrin ring function ) . The table The process allows control of Average Degree of Substitu shows these values up to the SBE - B - CD prepared using the 
method of the invention , having a surprisingly high IDS = 13 ntion by varying the sodium hydroxide concentration . The 
species . process can be used to produce material with a high Average The values of individual degree of substitution ( IDS ) and 5 Substitution Molecular Mass Fraction ( SMF ) shown in the Degree of Substitution . It will be possible to manufacture 
above table have been plotted out on FIG . 28 , and the material compliant with the USP35 / NF30 specification for 
relationship can be seen . The inventors believe that , to date , as sulphobutylether B - cyclodextrin . The process enables the SBE - B - CD with an SMF greater than 0 . 57 has not been 65 
previously reported , and as such the composition is novel production of sulphobutylether ß - cyclodextrin on a ' just in 
per se . time ' , “ just enough ' basis in a small manufacturing footprint . 
US 10 , 239 , 961 B2 
25 26 
REFERENCES 5 . The method according to claim 1 , wherein the sul 
phoalkyl ether - ß - cyclodextrin comprises sulphobutyl ether 
J . Szeman , K . Csabai , K . Kekesi , L . Szente , G . Varga . B - cyclodextrin ( SBE - B - CD ) . 
“ Novel stationary phases for high - performance liquid 6 . The method according to claim 1 , wherein the activa 
chromatography . ” Journal of Chromatography A , 2006 : 5 tion reaction is conducted at atmospheric pressure , and 
76 - 82 . wherein the activation reaction is carried out in a first 
J . Szeman . T . Sohajda , E . Olah . E . Varga . K . Csabai , G . reservoir vessel at a temperature of about 50 to 95° C . 
Varga , L . Szente . “ Characterization of Randomly Substi 7 . The method according to claim 1 , wherein the molar 
tuted Anionic Cyclodextrin Derivatives with Different ratio of sultone to cyclodextrin is between about 7 : 1 and 
Analytical Methods . ” 16th International Cyclodextrin 10 33 : 1 . 8 . The method according to claim 1 , wherein the sul Symposium . Tianjin , China , 2012 . phoalkylation reaction is conducted at a temperature of 60 to All publications , patents , and patent applications cited in 100° C . , and wherein the sulphoalkylation reaction is con this specification are herein incorporated by reference as if ducted at atmospheric pressure . 
each individual publication , patent , or patent application 9 . The method according to claim 1 . wherein the average 
were specifically and individually indicated to be incorpo - 15 degree of substitution ( ADS ) of the sulphoalkyl ether B - cy 
rated by reference . The following United States Provisional clodextrin that is produced is greater than 7 . 
Patent Application is specifically incorporated by reference 10 . The method according to claim 1 , comprising reacting 
herein : U . S . 61 / 847 , 509 entitled “ CYCLODEXTRIN ” filed the cyclodextrin with sodium hydroxide to control the 
17 Jul . 2013 . The following United Kingdom Patent Appli average degree of substitution ( ADS ) of the sulphoalkyl 
cation is specifically incorporated by reference herein : GB 20 ether B - cyclodextrin produced in the sulphoalkylation reac 
1312737 . 8 filed 17 Jul . 2013 . tion between activated cyclodextrin and an alkyl sultone . 11 . A method of preparing a pharmaceutical composition , 
The invention claimed is : the method comprising preparing a pharmaceutical excipient 
1 . A method for preparing sulphoalkyl ether - ß - cyclodex comprising sulphoalkyl ether B - cyclodextrin ( SAE - B - CD ) , 
trin , the method comprising contacting cyclodextrin with a 25 by contacting cyclodextrin with a base to form activated 
cyclodextrin , and separately contacting the activated base to form activated cyclodextrin , and separately contact 
ing the activated cyclodextrin with an alkyl sultone to form cyclodextrin with an alkyl sultone to form sulphoalkyl 
ether - ß - cyclodextrin , characterised in that the activa sulphoalkyl ether - ß - cyclodextrin , characterised in that the 
activation reaction is carried out as a batch process and the tion reaction is carried out as a batch process and the 
sulphoalkylation reaction is carried out under continuous 30 sulphoalkylation reaction is carried out under continu 
ous flow conditions in a continuous stirred tank reactor flow conditions in a continuous stirred tank reactor ( CSTR ) 
or a flow reactor with efficient mixing and of suitable length ( CSTR ) or a flow reactor with efficient mixing and of 
to allow the sulphoalkylation reaction to complete within the suitable length to allow the sulphoalkylation reaction to 
complete within the reactor tubing , wherein the acti reactor tubing ; wherein the activation reaction is carried out 
vation reaction is carried out in a first reservoir vessel , in a first reservoir vessel , and the alkyl sultone is contained 35 
and the alkyl sultone is contained within a second within a second reservoir vessel , and the first and second 
reservoir vessel , and the first and second vessels are not vessels are not directly connected to each other , such that the directly connected to each other , such that the sultone sultone and the base do not react with each other . 
2 . The method according to claim 1 , wherein the base and the base do not react with each other ; and 
comprises an alkali metal hydroxide , such as sodium 40 contacting the pharmaceutical excipient with an active 
hydroxide , lithium hydroxide or potassium hydroxide , and pharmaceutical ingredient ( API ) to produce a pharma 
wherein the molar ratio of base to cyclodextrin is within the ceutical composition . 
range of 2 : 1 to 22 : 1 , or 6 : 1 to 20 : 1 , or 6 : 1 to 15 : 1 . 12 . The method according to claim 11 , wherein the active 
3 . The method according to claim 1 , wherein the method pha pharmaceutical ingredient comprises voriconazole , ziprasi 
comprises controlling the average degree of substitution 45 do on 45 done , aripiprazole , maropitant , amiodarone , or carfilzomib , ( ADS ) of sulphoalkyl ether B - cyclodextrin in the sul or their salts , solvates , polymorphs , pseudopolymorphs or 
phoalkylation reaction by varying the base concentration in co - crystals . 13 . The method according to claim 1 , wherein no addi the activation reaction . 
4 . The method according to claim 1 , wherein cyclodextrin in tional base is added while the sulphoalkylation reaction is is B - cyclodextrin , and wherein the alkyl sultone comprises 50 carried out . 
1 , 4 - butane sultone . 
